Vyne Therapeutics Inc. (VYNE)

Market Closed

17 Jul, 20:00

NASDAQ (CM)

0. 76

-0.01

-0.9115%

11.85M Market Cap

- P/E Ratio

- Div Yield

996,000 Volume

-1 Eps

$ 0.77

Previous Close

Investors:

Add Transaction

Day Range

0.74 0.78

Year Range

0.28 1.59

Want to track VYNE and more in your Portfolio? 🎯

Get Started For Free

VYNE Therapeutics Inc. (VYNE) Yarrow Bioscience, Inc. - M&A Call Prepared Remarks Transcript

Seekingalpha | 7 months ago

VYNE Therapeutics Inc. (VYNE) Reports Q3 Loss, Tops Revenue Estimates

VYNE Therapeutics Inc. (VYNE) came out with a quarterly loss of $0.17 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to a loss of $0.29 per share a year ago.

Zacks | 8 months ago

VYNE Therapeutics Inc. (VYNE) Reports Q2 Loss, Lags Revenue Estimates

VYNE Therapeutics Inc. (VYNE) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.23. This compares to a loss of $0.22 per share a year ago.

Zacks | 11 months ago

VYNE Therapeutics Inc. (VYNE) Reports Q3 Loss, Tops Revenue Estimates

VYNE Therapeutics Inc. (VYNE) came out with a quarterly loss of $0.29 per share versus the Zacks Consensus Estimate of a loss of $0.24. This compares to loss of $1.85 per share a year ago.

Zacks | 1 year ago

VYNE Therapeutics Inc. (VYNE) Reports Q2 Loss, Tops Revenue Estimates

VYNE Therapeutics Inc. (VYNE) came out with a quarterly loss of $0.22 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to loss of $3.08 per share a year ago.

Zacks | 1 year ago

Blog Affiliate Program About Terms Privacy Help Contact Us